MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
LEVADEX Analysis Shows Potential to Treat a Broad Spectrum of Migraine
***UPDATED SATELLITE COORDINATES***
Migraine is a common, debilitating neurological disorder that affects
approximately 30 million people in
National Headache Foundation. Limitations of oral triptans, the class of
prescription drugs widely used for migraines, include slow onset of
significant pain relief between 45 and 90 minutes, substantial variability in
patient response and side effects such as heightened blood pressure.
MAP Pharmaceuticals, Inc. will present analysis of data from the efficacy
portion of the first Phase 3 trial of LEVADEX(TM) at the 14th Congress of the
International Headache Society. Data from this Phase 3 trial show the
potential of LEVADEX to be effective in treating acute migraine as well as a
broad spectrum of migraine, including migraine subpopulations that are often
resistant to current therapies, migraine with moderate and severe pain,
migraine with nausea and vomiting, and migraine with and without aura.
LEVADEX is an orally inhaled migraine therapy that patients administer
themselves using the company’s proprietary TEMPO(R) inhaler.
SATELLITE FEED: Thursday, September 10th, 2009 2:00 PM - 2:15 PM ET Galaxy 19 C-Band Transponder 10 Downlink Freq. 3900 Horizontal
NEWS: New Data Presented at the International Headache Society’s Annual
Congress Suggests New, Investigational Migraine Treatment Could Help Provide
Relief for 30 Million Sufferers in the U.S.
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at:
SOUNDBITES: * Dr. Stephen Silberstein, Director of the Headache Center, Jefferson University Hospitals * Migraine patient B-ROLL INCLUDES: * Dr/Patient footage * MAP corporate headquarters - exteriors and lab footage * manufacturing footage * product shots
VIDEO PROVIDED BY: MAP Pharmaceuticals, Inc.
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,
1-800-653-5313 EXT. 3
SOURCE MAP Pharmaceuticals, Inc.